InChI
1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45-,49+,50+,51-,52+/m1/s1
InChI key
CFCUWKMKBJTWLW-WZIVUMCRSA-N
assay
≥98% (HPLC)
form
powder
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
yellow
solubility
DMSO: 50 mg/mL
Quality Level
General description
An aureolic acid type tricyclic pentaglycoside antibiotics with anti-tumor properties. Binds to G-C rich DNA and displaces Sp1 transcription factor from its sites in the promoters of selected oncogenes, such as c-Myc and c-Src. Mithramycin A-induced inhibition of Sp1 activity has been linked to greater DNA damage and cell death in cells that are homozygous for SNP309. Specifically reduces the levels of MDM2 in human ductal breast epithelial tumor cell line, T47D (5-fold reduction at 200 nM), but does not affect cells that are wild-type for SNP309. Shown to induce myeloid differentiation of leukemic blasts that leads to reduction in the level of expression of c-Myc and c-Abl proto oncogenes that harbor G-C rich promoters. Inhibits Mcl-1 activity and mTOR phosphorylation (Ser2448) in prostate cancer cells without affecting normal human prostate epithelial cells. Shown to reduce expression of endogenous transient receptor potential vanilpod receptor (TRPV1)-like protein in dorsal root ganglionic neurons.
Biochem/physiol Actions
Primary Target
Sp1 transcription factor
Sp1 transcription factor
Reversible: yes
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Zavala, K., et al. 2014. Neurosci Lett.562,in press.
Choi, E. S., et al. 2013. J. Clin. Biochem. Nutr.53, 89.
Sleiman S. F., et al. 2011. J. Neurosci.31, 6858.
Bond, G, et al. 2004. Cell.119, 591.
Blume, S, et al. 1991. J. Clin. Invest.88, 1613.
Choi, E. S., et al. 2013. J. Clin. Biochem. Nutr.53, 89.
Sleiman S. F., et al. 2011. J. Neurosci.31, 6858.
Bond, G, et al. 2004. Cell.119, 591.
Blume, S, et al. 1991. J. Clin. Invest.88, 1613.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful & Carcinogenic / Teratogenic (E)
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持